Supplementary materials (9).docx (13.09 kB)

Cost–effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score ≥10 - Supplementary materials

dataset

posted on 2022-08-31, 08:51 authored by Qian Xie, Xingchen Peng

Transition probability of progressive free status to progressive free status(pFTF), progressive free status to death(pFTD), progressive free status to progressive status(pFTP)

Funding

Sichuan Province Science and Technology Support Program, (Grant / Award Number)

History

Usage metrics

Keywords

cost–effectiveness analysis gastroenterology/hepatology health policy oncology

Licence

CC BY-NC-ND 4.0